Johnson & Johnson (NYSE:JNJ) shares surged 3.57% on Thursday, closing at $263.04, a level that places the stock above the average analyst price target of $262.10 as compiled by The Wall Street Journal. The session high of $263.10 matched the stock's 52-week peak, adding approximately $21.8 billion to the company's market capitalization based on its 2.41 billion outstanding shares.
Market Context and Performance
The pharmaceutical and medical device giant's advance outpaced broader market indices. The Dow Jones Industrial Average gained 1.14%, while the S&P 500 ended nearly flat. The Nasdaq Composite declined 0.80%, and the Health Care/Life Sciences sector slipped 0.25%. Trading volume for JNJ reached 7.9 million shares, just below the 65-day average.
Despite the strong single-session move, investors are now focused on the stock's current valuation relative to analyst expectations. With the close at $263.04, shares sit just $1.96 below the median target of $265.00. The high target stands at $289.00, representing a 9.9% upside, while the low target of $210.00 is 20.2% below the current price.
Earnings Outlook
The proximity to analyst targets comes as Johnson & Johnson prepares to report second-quarter results on July 15, 2026, at 8:30 a.m. ET. According to WSJ data, the consensus estimate for Q2 earnings per share stands at $2.85, unchanged from a month ago but down from $2.89 three months prior. For the full year 2026, the EPS estimate is $11.58, barely moved from $11.56 three months back.
In April, the company raised its 2026 guidance, projecting reported sales of $100.8 billion and adjusted EPS of $11.55 at the midpoint. CEO Joaquin Duato characterized the start of 2026 as "strong." First-quarter results showed Innovative Medicine sales of $15.43 billion, up 11.2% year-over-year, and MedTech sales of $8.64 billion, a 7.7% increase. Worldwide sales reached $24.06 billion, a 9.9% gain.
Broader Market Influences
The broader market saw mixed performance, with technology stocks under pressure. Reuters reported continued selling in chipmakers, weighing on the Nasdaq. "You can really point the finger at the consolidation in the chips," said Bruce Zaro, managing director at Granite Wealth Management. Meanwhile, a weaker-than-expected jobs report "takes the pressure off the Fed to raise rates in the short term," according to Adam Sarhan, CEO at 50 Park Investments.
Thursday marked the last full trading day before the long Independence Day weekend, with both the NYSE and Nasdaq closed on Friday, July 3, 2026.
